You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
SBC: OASIS PHARMACEUTICALS, LLC Topic: NHLBIDespite prevalent use of anti-platelet and anti-lipid therapies, stroke remains the third major cause of death and is the leading cause of adult disability in the US with an estimated cost in the range of $34 billion annually. Approximately 20% of the annual 795,000 stroke patients die within one year and 15-30% are permanently disabled. Antiplatelet therapy is mainly used for primary prevention o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide
SBC: OUI THERAPEUTICS INC Topic: 104ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects
SBC: General Biophysics LLC Topic: NIAPHASE II APPLICATION(STTR Program PAS-22-197) “Phase 1 Trial to Assess Safety and Immune Effects of Xenon Gas in Healthy Human Subjects” ABSTRACTAlzheimer’s disease (AD) is one of the most prevalent neurodegenerative disorders. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant role in the onset an ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent
SBC: PACDNA LLC Topic: NCIProject Summary/Abstract Mutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeuticintervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a singlemutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitorshas heightened the importance of alternative methods targeting the o ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia
SBC: HOPEFUL AGING LLC Topic: RPROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, and Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly impact ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Field Instrument for Assessment of Arsenic Exposure
SBC: GINER INC Topic: RProject Summary Human exposure to toxic heavy metals existing in drinking water, food, and the environment is an area of increasing national and international concern. Heavy metals are significant environmental pollutants because they tend to persist, bioaccumulate and can result in serious adverse acute or chronic health effects after ingested or inhaled. Traditionally, trace metals are measured ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Noregen, a regenerative medicine ocular therapeutic
SBC: Retinal Solutions LLC Topic: NEIABSTRACT Ischemic retinopathies, such as diabetic retinopathy and retinal vein occlusion, are the leading cause of blindness in the United States. Common features are leaky vessels, swelling, capillary drop out, aberrant vessel growth and retinal detachment. Current treatments include laser ablation, anti-VEGFs and steroids. All are sub-optimal and only serve to slow disease progression and vision ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
New generation of catheters for treatment of atrial fibrillation
SBC: LUXMED SYSTEMS INC Topic: NHLBIABSTRACT Atrial fibrillation (AF) remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality primarily due to poor hemodynamic performance and often stroke. One of the primary options to treat AF is cardiac ablation where the physician applies radiofrequency energy via percutaneous catheters to form a series of ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke
SBC: NUVOX PHARMA, L.L.C. Topic: NINDSABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Platform for the High Throughput Generation and Validation of Affinity Reagents
SBC: ABBRATECH INC. Topic: 300ABSTRACT We present a complete platform for the rapid generation and validation of recombinant mAbs. The innovations of this proposal include: (1) the pATHENA vector system for overnight conversion of phage display scFv or Fab clones into IgG molecules, (2) the Epivolve method for the isolation of site-specific Abs, (3) the incorporation of yeast display into pATHENA to allow biophysical measureme ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health